Medicovestor, Inc., a pioneering biotech start-up, develops novel Antibody Drug Conjugate (ADC) platforms to address therapeutic gaps in existing ADCs. Leveraging diverse expertise and experience, our team minimizes risks and maximizes success probabilities. Led by a driven C-suite, strengths include translational medicine, antibody engineering, US regulatory prowess, and clinical expertise. Our innovative platforms, ADoBind and ADoFuse, have transformative potential across disease indications.